Botox, Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B) have recently been linked to possible life-threatening side effects including respiratory failure and death.
Botox is manufactured by Allergan Inc for both medical as well as cosmetic use. A report was recently released by the U.S. Food and Drug Administration in order to inform the public of the adverse reactions linked to the use of Botox, Botox Cosmetic, and Myobloc.
What is the problem with Botox?
Botulinum toxin is a neurotoxin protein produced by the bacterium Clostridium botulinum. It is sold commercially under the brand name Botox. Botox has been approved by the FDA to be used in very small doses both to treat painful muscle spasms and as a cosmetic treatment. It is used in the treatment of migraine headaches, blepharospasm, cervical dystonia, and many other medical issues. Since 2006, Botox has been the most commonly used cosmetic treatment in the United States. Botox has also been used in treatments not approved by the FDA such as treatment of limb spasticity of cerebral palsy or for use in any condition in children less than 12 years of age. The FDA’s public notification came after severe, adverse reactions were found in both FDA-approved and non FDA-approved usages. The most severe reactions were found in children after the treatment of limb spasticity of cerebral palsy. These adverse reactions are occurring after the toxin spreads in areas away from the injection site. The FDA is not advising health care professionals to discontinue prescribing these products as they have not fully completed their investigation.